(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 8 May 2003 (08.05.2003)

(10) International Publication Number WO 2003/037913 A3

(51) International Patent Classification⁷: A61K 39/395, C07K 16/28, C07H 21/04, C12P 21/06

(21) International Application Number:

PCT/US2002/035333

(22) International Filing Date:

1 November 2002 (01.11.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/346,402

1 November 2001 (01.11.2001)

(71) Applicant (for all designated States except US): UAB RESEARCH FOUNDATION [US/US]; 701 South 20th Street, Suite 1120G, Birmingham, AL 35294 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ZHOU, Tong [CH/US]; 332 West Stonebrook Place, Birmingham, AL 35226 (US). KIMBERLY, Robert, P. [US/US]; 2045 Magnolia Ridge, Birmingham, AL 35243 (US). KOOP-MAN, William, J. [US/US]; 187 Wildwood Avenue, Indian Springs, AL 35124 (US). LOBUGLIO, Albert, F. [US/US]; 2204 Tanglewood Road, Birmingham, AL 35216 (US). BUCHSBAUM, Donald, J. [US/US]; 140 Windwood Circle, Montevallo, AL 35115 (US).

- (74) Agents: MCKEON, Tina, Williams et al.; Needle & Rosenberg, P.C., Suite 1000, 999 Peachtree Street, Atlanta, GA 30309-3915 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of
- (88) Date of publication of the international search report: 18 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AN ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF

(57) Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35333

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 39/395; C07K 16/28; C07H 21/04; C12P 21/06 US CL : 424/138.1,141.1,143.1,153.1,154.1,155.1,156.1,173.1,174.1; 530/387.3,388.22; 536/23.5; 435/69.1. According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIEL	DS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/138.1,141.1,143.1,153.1,154.1,155.1,156.1,173.1,174.1; 530/387.3,388.22; 536/23.5; 435/69.1.				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where a		Relevant to claim No.	
X P,X	column 31, line 48. 91,94 US 6,461,823 A (NI et al) 08 October 2002 (08.10.2002), column 4, Lines 1-7, column 26, 1-16		1-7, 10, 58, 59, 85,88- 91,94-97,100,101,104 1-10,58, 59,85,89-	
Y	Lines 29-49. SONG et al. Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Is an Inhibitor of Autoimmune Inflammation and Cell cycle Progression. 03 April 2000, Vol. 191, No. 7, pages 1095-1103, especially pages 1095 and 1100.			
Y	PAN et al. The Receptor of the Cytotoxic Ligand T 276, Issue 5309, pages 111-113, see entire documen		1	
Further	documents are listed in the continuation of Box C.	See patent family annex.	٠	
* S ₁	pecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the applic		
	defining the general state of the art which is not considered to be lar relevance	principle or theory underlying the inve	ention	
• •	plication or patent published on or after the international filing date	considered novel or cannot be consider when the document is taken alone		
establish (specified)		"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is documents, such combination	
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	e art	
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family		
Date of the actual completion of the international search 12 September 2004 (12.09.2004)		Date of mailing of the international search	ch report	
Name and applies address of the ISA/IIS Atthorized officer				
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Anne Holleran Fautherick for		
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Telephone No. (571) 272-1600		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35333

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet			
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

INTERNATIONAL SEARCH REPORT				
BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LAC This application contains the following inventions or groups of inventions which are concept under PCT Rule 13.1. In order for all inventions to be examined, the appro	e not so linked as to form a single general inventive			
Group I, claim(s) 1-10, 58, 59 and 97-104, drawn to an antibody that bind DR4 and has in vivo and in vitro apoptosis-inducing activity.				
Group II, claim(s) 11-57 and 60-84, drawn to drawn to methods of treatment using an antibody that binds DR4.				
Group III, claim(s) 85-96, drawn to nucleic acids encoding heavy chains or light chains of antibodies that bind to DR4 and capable of inducing apoptosis.				
The inventions listed as Groups I, II, and III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I, II and III are not linked by a special technical feature that provides a contribution over the prior art, because antibodies that bind to DR4 and that are agonist antibodies (i.e. induce apoptosis) are known in the art as evidenced by the teachings of Ashkenazi (U.S. Patent 6,252,050; issued June 26, 2001; see col. 22, line 63 - col. 24, line 65 and col. 30, lines 9-21 and col. 31, lines 33-43, Table 3).				
Continuation of B. FIELDS SEARCHED Item 3: Medline, Embase, Biosis, Caplus, US Patents Database (EAST) search terms: dr4, apo-21, apoptosis, trail, 2e12				

PCT/US02/35333